Starpharma Continues VIRALEZE success in December quarter
- Starpharma (SPL) releases its September quarterly report, with the period again highlighted by the continued success of VIRALEZE
- In late July, VIRALEZE showed a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2, the virus that causes COVID-19
- The VIRALEZE antiviral nasal spray is expected to be launched in Vietnam and Italy next month and SPL is in discussions with other markets in Asia, Europe and India
- As of September 30, the platform had more than $53.61 million in total available funding, representing 7.6 quarters of use if spending levels remain the same
- The platform is steady on the market with shares trading at $1.07
